Row 3596

Row ID: 3596 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 3596 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

I'm trying to devise the criteria for my national immunisation technical advisory group (NITAG) to determine when an economic evaluation of a new vaccine is needed in the decision-making process. I think this can be generalised to the introduction of any healthcare intervention, but right now I'm thinking about vaccines.

Our NITAG doesn't have any such guidelines or criteria right now. We'll always consider vaccine safety, vaccine efficacy, immune response induced and things like that from the pivotal clinical trials. Occasionally we need to consider the potential acceptance of a new vaccine if there might be some push-back or controversy, sometimes we'll look at the justifications for recommendations for the same vaccine when used abroad, but there's no formal process to follow for aspects like that. I'd like to get one developed for economic evaluations.

Some NITAGs, like the JCVI in the UK, require economic evaluations by default. For us, occasionally we'll consider cost-effectiveness but we also don't have the right to not recommend a new vaccine if it appears to be not cost-effective. We also don't use a threshold for ICERs to determine cost-effectiveness, so a vaccine with an ICER of >200,000 € per QALY saved (for example) could still be recommended to a large target population. In other countries that would be rejected flat-out.

When trying to find literature on this topic all I can find is guidelines for conducting economic evaluations (Drummond et al., etc), but nothing yet for deciding if one is necessary.

Does anyone have any experience in this domain please?

FieldValue
text I'm trying to devise the criteria for my national immunisation technical advisory group (NITAG) to determine when an economic evaluation of a new vaccine is needed in the decision-making process. I think this can be generalised to the introduction of any healthcare intervention, but right now I'm thinking about vaccines. Our NITAG doesn't have any such guidelines or criteria right now. We'll always consider vaccine safety, vaccine efficacy, immune response induced and things like that from the …
label r/epidemiology
dataType post
communityName r/epidemiology
datetime 2024-03-15
username_encoded Z0FBQUFBQm5LakwxZk5nY1E2WUk3Y2RuY1NseEJ6b3Bwd2N6YUcwNVRrMDdJaG5YTkREUm8xajNnNVU0VGNXd1FVbVc3NkY3ZTQycV9wZEZqUDVxNnBadnYyd1d6ZGhoWXc9PQ==
url_encoded Z0FBQUFBQm5Lak9FQmFTNkQ1WlRoUHBLWU5VQjdObklYNFJNQUI1SEV0QkpFNDdEaDlTTkFnalhsVzl2Ul9FazM4TVdnTHF1dEUycGFCWUh4alZwcTR2bGNrZENIdGw0SmpncjBDUEFBQ2FjckNQeEtzQm9uczc5cDVTdlVtZkd0Y1JJSGFDVnpXNUFwVmoybU5XWXpMM0JVTU9vYUNoanpDUFQ3ZEJNNy1mSUEzLTVOWVNURnlqZzdjT3FlX3hTRHlyejdaU1hRdWI3VmFuR3pzQ2FVakI5U0swa1ZQWHNpdz09

Raw Record

{
  "text": "I'm trying to devise the criteria for my national immunisation technical advisory group (NITAG) to determine when an economic evaluation of a new vaccine is needed in the decision-making process. I think this can be generalised to the introduction of any healthcare intervention, but right now I'm thinking about vaccines.\n\nOur NITAG doesn't have any such guidelines or criteria right now. We'll always consider vaccine safety, vaccine efficacy, immune response induced and things like that from the pivotal clinical trials. Occasionally we need to consider the potential acceptance of a new vaccine if there might be some push-back or controversy, sometimes we'll look at the justifications for recommendations for the same vaccine when used abroad, but there's no formal process to follow for aspects like that. I'd like to get one developed for economic evaluations.\n\nSome NITAGs, like the JCVI in the UK, require economic evaluations by default. For us, occasionally we'll consider cost-effectiveness but we also don't have the right to not recommend a new vaccine if it appears to be not cost-effective. We also don't use a threshold for ICERs to determine cost-effectiveness, so a vaccine with an ICER of >200,000 € per QALY saved (for example) could still be recommended to a large target population. In other countries that would be rejected flat-out.\n\nWhen trying to find literature on this topic all I can find is guidelines for conducting economic evaluations (Drummond et al., etc), but nothing yet for deciding if one is necessary.\n\nDoes anyone have any experience in this domain please? ",
  "label": "r/epidemiology",
  "dataType": "post",
  "communityName": "r/epidemiology",
  "datetime": "2024-03-15",
  "username_encoded": "Z0FBQUFBQm5LakwxZk5nY1E2WUk3Y2RuY1NseEJ6b3Bwd2N6YUcwNVRrMDdJaG5YTkREUm8xajNnNVU0VGNXd1FVbVc3NkY3ZTQycV9wZEZqUDVxNnBadnYyd1d6ZGhoWXc9PQ==",
  "url_encoded": "Z0FBQUFBQm5Lak9FQmFTNkQ1WlRoUHBLWU5VQjdObklYNFJNQUI1SEV0QkpFNDdEaDlTTkFnalhsVzl2Ul9FazM4TVdnTHF1dEUycGFCWUh4alZwcTR2bGNrZENIdGw0SmpncjBDUEFBQ2FjckNQeEtzQm9uczc5cDVTdlVtZkd0Y1JJSGFDVnpXNUFwVmoybU5XWXpMM0JVTU9vYUNoanpDUFQ3ZEJNNy1mSUEzLTVOWVNURnlqZzdjT3FlX3hTRHlyejdaU1hRdWI3VmFuR3pzQ2FVakI5U0swa1ZQWHNpdz09"
}
Explore Dataset Explore Row

Entry Information